Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2017

May 16, 2017

33483_dirs_2017-05-16_14d66e9b-92b1-433e-a54e-9a4c4fefec80.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2017-05-16

Reporting Person: KANIA EDWIN M JR (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-05-16 Common Stock S 266795 $14.00 Disposed 560067 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 26528 Direct

Footnotes

F1: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Mr. Kania disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F2: Includes 26,528 shares that was previously received by Mr. Kania in a pro rata distribution by Flagship 2007 LLC that was exempt from reporting pursuant to Rule 16a-13.